Immuneering (NASDAQ:IMRX - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Immuneering to post earnings of ($0.41) per share for the quarter.
Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.16). On average, analysts expect Immuneering to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Immuneering Price Performance
IMRX opened at $1.45 on Tuesday. The firm has a 50 day moving average price of $1.50 and a 200-day moving average price of $1.84. Immuneering has a twelve month low of $1.00 and a twelve month high of $3.83. The stock has a market capitalization of $52.18 million, a price-to-earnings ratio of -0.74 and a beta of -0.25.
Analyst Ratings Changes
IMRX has been the subject of several recent research reports. Needham & Company LLC restated a "buy" rating and set a $12.00 target price on shares of Immuneering in a research report on Thursday, April 10th. Chardan Capital reiterated a "buy" rating and issued a $13.00 price target on shares of Immuneering in a research report on Monday, March 24th.
Check Out Our Latest Stock Analysis on IMRX
Immuneering Company Profile
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
